# A Phase IIb Study to Evaluate Efficacy and Tolerability of ODX (Osteodex) in Metastatic CRPC

> **NCT02378870** · PHASE2 · TERMINATED · sponsor: **DexTech Medical AB** · enrollment: 3 (actual)

## Conditions studied

- Prostate Cancer Metastatic

## Interventions

- **DRUG:** Osteodex
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02378870
- **Lead sponsor:** DexTech Medical AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-01
- **Primary completion:** 2015-06
- **Final completion:** 2015-09
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Poor patient recruitment
- **Last updated:** 2016-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02378870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02378870, "A Phase IIb Study to Evaluate Efficacy and Tolerability of ODX (Osteodex) in Metastatic CRPC". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02378870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*